Difference between revisions of "Team:UofC Calgary"
| Line 286: | Line 286: | ||
padding: 0px 20px 20px;"> | padding: 0px 20px 20px;"> | ||
| − | <p style="color: #273236">Mars and the cosmos are a tantalizingly close goal for Mankind to reach in the next century; however, there are several glaring problems that we must overcome to reach such an objective. Radiation is chief among them. On Earth, individuals annually receive 2.4 mSv of ionizing radiation (IR), which is easily tolerated by the human body. Unfortunately, without the protection of the magnetosphere, astronauts in space are exposed to high levels of IR in the range of 50 to 2000 mSv. This level of radiation causes the accumulation of deleterious double strand breaks in DNA. Despite current research into methods of IR protection, many solutions such as radiation shield coating are quite expensive, especially to transport to space. | + | <p style="color: #273236">Mars and the cosmos are a tantalizingly close goal for Mankind to reach in the next century; however, there are several glaring problems that we must overcome to reach such an objective. Radiation is chief among them. On Earth, individuals annually receive 2.4 mSv of ionizing radiation (IR), which is easily tolerated by the human body. Unfortunately, without the protection of the magnetosphere, astronauts in space are exposed to high levels of IR in the range of 50 to 2000 mSv. This level of radiation causes the accumulation of deleterious double strand breaks in DNA. Despite current research into methods of IR protection, many solutions such as radiation shield coating are quite expensive, especially to transport to space. Even existing biological solutions are insufficient, such as the use of ingestible or injectable radioprotectors, which are subject to sinusuoidal pharmacokinetics. Our project is based on the administration of the naturally occuring peptide Bowman-Birk Protease Inhibitor (BBI), which has been shown to confer protection against DNA damage following radiation exposure. (Dittmann <i>et al.</i>, 2003)</p> |
| − | + | ||
| − | + | ||
| − | + | ||
</div> | </div> | ||
</div> | </div> | ||
| Line 311: | Line 308: | ||
padding: 0px 20px 20px;"> | padding: 0px 20px 20px;"> | ||
| − | <p style="color: #FFFFFF">We designed our project to overcome common issues in existing technologies such as cost, portability and durability. Our solution is superior to current technologies because our patch is portable, lightweight, safe to use, can be stored long-term, and produces and delivers peptides at a steady rate, which solves the issues of pharmacokinetics. We worked with professionals within NASA and the CSA to integrate our solution with current space travel infrastructure, and with companies specializing in transdermal delivery to optimize the delivery system. </p> | + | <p style="color: #FFFFFF"><br><br><br><br>We designed our project to overcome common issues in existing technologies such as cost, portability and durability. Our solution is superior to current technologies because our patch is portable, lightweight, safe to use, can be stored long-term, and produces and delivers peptides at a steady rate, which solves the issues of pharmacokinetics. We worked with professionals within NASA and the CSA to integrate our solution with current space travel infrastructure, and with companies specializing in transdermal delivery to optimize the delivery system. <br><br><br><br><br></p> |
</div> | </div> | ||
</div> | </div> | ||
Revision as of 02:50, 18 October 2016
Our Project
Project Description
Mars and the cosmos are a tantalizingly close goal for Mankind to reach in the next century; however, there are several glaring problems that we must overcome to reach such an objective. Radiation is chief among them. On Earth, individuals annually receive 2.4 mSv of ionizing radiation (IR), which is easily tolerated by the human body. Unfortunately, without the protection of the magnetosphere, astronauts in space are exposed to high levels of IR in the range of 50 to 2000 mSv. This level of radiation causes the accumulation of deleterious double strand breaks in DNA. Despite current research into methods of IR protection, many solutions such as radiation shield coating are quite expensive, especially to transport to space.
Biological solutions, such as the use of ingestible or injectable radioprotectors, are subject to sinusoidal pharmacokinetics. The therapeutic is delivered once, and although it may be effective initially, it will be degraded over time by the body, dropping its efficiency rate. This results in the need to re-administer a drug regularly to maintain its activity in the body, so the dosage level resembles a sinusoidal curve. Certain naturally-occurring proteins and peptides, such as the Bowman-Birk Protease Inhibitor (BBI), have been found to confer protection against DNA damage in cells exposed to ionizing radiation. Previous studies have shown that BBI increases the survival rate of cells significantly after they are irradiated by augmenting endogenous DNA repair mechanisms (Dittmann et al., 2003).
To create a cost effective and continuous delivery system for IR protection during space travel, we have designed a transdermal patch for the delivery of a modified version of BBI (mBBI) through the skin. The patch hosts recombinant Bacillus subtilis cells that express mBBI with a transdermal tag that allows the peptide to travel through the layers of the skin and into the bloodstream for dispersal throughout the body. This recombinant protein is fused to a B. subtilis-specific secretory tag, which permits the peptide to be secreted into the growth medium. Using B. subtilis for the production of mBBI allows for constant delivery and resolves the issue of sinusoidal pharmacokinetics. This long term, continuous delivery is also cost effective and minimizes waste. Ultimately, our transdermal delivery patch allows for the administration of biotherapeutics within an efficient and practical system, while maintaining the flexibility of modularity, as B. subtilis could be used to produce a multitude of various peptides or small molecules with various therapeutic effects.
References
Dittmann, K.H., Mayer, C., and Rodemann, H.P. (2003). Radioprotection of normal tissue to improve radiotherapy: the effect of the Bowman Birk protease inhibitor. Current Medicinal Chemistry - Anticancer Agents, 3(5), 360-363.
OUR CHASSIS
Mars and the cosmos are a tantalizingly close goal for Mankind to reach in the next century; however, there are several glaring problems that we must overcome to reach such an objective. Radiation is chief among them. On Earth, individuals annually receive 2.4 mSv of ionizing radiation (IR), which is easily tolerated by the human body. Unfortunately, without the protection of the magnetosphere, astronauts in space are exposed to high levels of IR in the range of 50 to 2000 mSv. This level of radiation causes the accumulation of deleterious double strand breaks in DNA. Despite current research into methods of IR protection, many solutions such as radiation shield coating are quite expensive, especially to transport to space. Even existing biological solutions are insufficient, such as the use of ingestible or injectable radioprotectors, which are subject to sinusuoidal pharmacokinetics. Our project is based on the administration of the naturally occuring peptide Bowman-Birk Protease Inhibitor (BBI), which has been shown to confer protection against DNA damage following radiation exposure. (Dittmann et al., 2003)
Design Overview
We designed our project to overcome common issues in existing technologies such as cost, portability and durability. Our solution is superior to current technologies because our patch is portable, lightweight, safe to use, can be stored long-term, and produces and delivers peptides at a steady rate, which solves the issues of pharmacokinetics. We worked with professionals within NASA and the CSA to integrate our solution with current space travel infrastructure, and with companies specializing in transdermal delivery to optimize the delivery system.
Our Project
Project Description
Our Experiments
Modelling
Human Practices
About us
The 2016 U of C Calgary iGEM team is a multidisciplinary team based out of the University of Calgary. Our team is made up of undergraduate students from all years of study, hailing from the broad backgrounds of biology, microbiology, biomedical sciences, bioinformatics, and engineering. We are based out of the O'Brien Centre Labs within the U of C's Health Science Centre.
Our Sponsors
